Recent Quotes (30 days)

You have no recent quotes
chg | %

Shire PLC news

   Watch this stock
Showing stories 1 - 10 of about 113   

Articles published

SHP 4,916.00 +1.00 (0.02%)
price chart
Invesco European Growth Fund Comments on Shire PLC
Shire PLC (LSE:SHP) and Haci Omer Sabanci Holding AS were among the most significant individual contributors to fund performance during the quarter (2.08% and 1.88% of total net assets, respectively.
Related articles »  
Why Are Shire PLC Shares Trading So Far Below The AbbVie Offer Price?
In a footnote to Shire's most recent update, the company says that any firm offer from AbbVie needs to be the greater of �46.26, or the sum of �24.44, plus the value of 0.8960 AbbVie shares at time of the offer.
Shire ready to bow to AbbVie's increased $53 billion offer  Reuters
If AbbVie Succeeds There Could Be a Homecoming for Shire  Wall Street Journal (blog)
Related articles »  
Which Bid Target Should You Buy: Shire PLC Or AstraZeneca plc?
shire It's been an extremely busy year for the healthcare sector, as bids for Shire (LSE: SHP) (NASDAQ: SHPG.US) and AstraZeneca (LSE: AZN) (NYSE: AZN.
AstraZeneca plc's Neutral Rating Reaffirmed at Credit Suisse (AZN)  Watch List News (press release)
Related articles »  
The AbbVie Inc, Shire PLC, Merger Will Not Change The US Tax On US Profits
We hear this morning that AbbVie AbbVie has been successful in bidding for Shire Shire and that the newly merged company will arise, as a butterfly from a chrysalis, as a UK domiciled company.
Shire PLC Accepts �32bn Takeover By AbbVie Inc  Motley Fool UK
AbbVie Is Biggest to Quit US Address in $55 Billion Shire Deal  Bloomberg
Related articles »  
3 Reasons Why You Should Sell Shire PLC
Shire (LSE: SHP) (NASDAQOTH: SHPG.US) shareholders have seen the value of their stock rise by 60% this year, thanks mainly to a takeover bid from US firm AbbVie.
AbbVie: Barclays Is Late To Upgrade, Using Highly Favorable Assumptions  Seeking Alpha
Related articles »  
AbbVie Will Make Another Attempt To Buy Shire PLC
Indeed, it is now widely believed that the US pharmaceutical giant will return to make another bid for Shire. City analysts believe the AbbVie could offer as much as �62.00 per share for Shire, a 34% premium to the previous offer of �46.26 per share.
Related articles »  
Shire seeks AbbVie bid of close to 53 pounds per share - sources
NEW YORK (Reuters) - Shire Plc (SHP.L) is seeking a higher takeover offer from U.S. drugmaker AbbVie Inc (ABBV.N) that would value the company at about 31 billion pounds ($53 billion), according to people familiar with the matter.
Shire Plc (SHPG) Soared To A New High On AbbVie Talks  RTT News
AbbVie Nudges Top Shire Shareholders to Push Deal Talks  Businessweek
Related articles »  
Shire PLC's Market Perform Rating Reaffirmed at Sanford C. Bernstein (SHP)
Sanford C. Bernstein restated their market perform rating on shares of Shire PLC (LON:SHP) in a report issued on Friday. They currently have a GBX 5,300 ($90.00) target price on the stock.
Shire PLC Given �Market Perform� Rating at Sanford C. Bernstein (SHP)  WKRB News
Research Analysts' Ratings Reiterations for July, 25th (AAL, ABF, ABG ...  Mideast Time
Related articles »  
Should You Invest In Shire PLC Instead Of GlaxoSmithKline plc And ...
AstraZeneca Nothing gets a share price moving upwards like a bid. Indeed, investors in Shire (LSE: SHP) and AstraZeneca (LSE: AZN) (NYSE: AZN.
Related articles »  
Is Hikma Pharmaceuticals Plc A Better Buy Than GlaxoSmithKline plc Or Shire ...
shire It's been a great first half of 2014 for investors in Hikma (LSE: HIK), with the pharmaceutical company seeing its share price rise by 47%, while the FTSE 100 is up just 1.5%.